Developing vaccines against flavivirus diseases: Past success, present hopes and future challenges

Novartis Foundation Symposium

Volumn 277, Issue , 2006, Pages 193-201

  Stephenson, John R ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

FLAVIVIRUS; HUMAN; IMMUNOLOGY; REVIEW; VIRUS INFECTION;

FLAVIVIRUS; FLAVIVIRUS INFECTIONS; HUMANS; VIRAL VACCINES;

EID: 33947546343     PISSN: 15282511     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (33)

1. Alcon S, Talarmin A, Debruyne M, Falconar A, Deubel V, Flamand M 2002 Enzyme-linked immunosorbent assay specific to Dengue virus type 1 non-structural protein NS1 reveals circulation of the antigen in the blood during the acute phase of disease in patients experiencing primary or secondary infections. J Clin Microbiol 40:376-381
2. Almond J, Clemens J, Engers H et al 2002 Accelerating the development and introduction of a dengue vaccine for poor children, 5-8 December 2001, Ho Chi Minh City. Vaccine 20:3043-3046
3. Amanna I, Slifka MK 2005 Public fear of vaccination: separating fact from fiction. Viral Immunol 18:307-315
4. Belongia EA, Naleway AL 2003 Smallpox vaccine: the good, the bad, and the ugly. Clin Med Res 1:87-92
5. Brotherston JG, Boyce JB 1969 Vet Rec 84:514-515
6. Daems R, Del Giudice G, Rappuoli R 2005 Anticipating crisis: Towards a pandemic flu vaccination strategy through alignment of public health and industrial policy. Vaccine 23:5732-5742
7. Freestone DS, Ferris RD, Weinberg AL, Kelly A 1977 Stabilised 17D strain yellow fever vaccine: dose response studies, clinical reactions and effect on hepatic function. J Biol Standard 5:181-186
8. Grosenbaugh DA, Backus CS, Karaca K, Minke JM, Nordgren RM 2003 Equine vaccine for West Nile virus. Dev Biol 114:221-227
9. Guirakhoo F, Pugachev K, Arroyo J et al 2002 Viremia and immunogenicity in nonhuman primates of a tetravalent yellow fever-dengue chimeric vaccine: genetic reconstructions, dose adjustment, and antibody responses against wild-type dengue virus isolates. Virology 298:146-159
10. Halstead SB 1982 Immune enhancement of viral infection. Prog Allergy 31:301-364
11. Halstead SB, Deen J 2002 The future of dengue vaccines. Lancet 360:1243-1245
12. Heinz FX, Kunz C, Fauma H 1980 Preparations of a highly purified vaccine against tick-borne encephalitis by continuous flow zonal ultracentrifugation. J Med Virol 6:103-221
13. Jacobs SC, Stephenson JR, Wilkinson GWG 1994 Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1. J Gen Virol 75:2399-2402
14. Jacobs M, Young P 2003 Dengue vaccines: preparing to roll back dengue. Curr Opin Investig Drugs 4:168-171
15. Klockmann U, Bock HL, Franke V, Hein B, Reiner G, Hilfenhaus J 1989 Preclinical investigations of the safety, immunogenicity and efficacy of a purified, inactivated tick-borne encephalitis vaccine. J Biol Standard 17:331-342
16. Lin CF, Lei HY, Shiau AL et al 2003 Antibodies from dengue patient sera cross-react with endothelial cells and induce damage. J Med Virol 69:82-90
17. Lobigs M, Arthur CE, Muellbacher A, Blanden RV 1994 The flavivirus non-structural protein NS3 is a dominant source of cytotoxic T cell peptide determinants. Virol 202:195-201
18. Monath TP 2002 Japanese encephalitis vaccines: current vaccines and future prospects. Curr Topics Microbiol Immunol 267:105-138
19. Mongkolsapaya J, Dejnirattisai W, Xu X et al 2003 Original antigenic sin and apoptosis in the pathogenesis of dengue haemorrhagic fever. Nature Med 9:921-927
20. Ng T, Hathaway D, Jennings N, Champ D, Chiang YW, Chu HJ 2004 The anamnestic serologic response to vaccination with a canarypox virus-vectored recombinant West Nile virus (WNV) vaccine in horses previously vaccinated with an inactivated WNV vaccine. Vet Ther 5:251-257
21. Popov OV, Sumarakov AA, Shkol'nik RYa, El'bert LB, Vorob'era MA, Krutyanskaya GL 1985 Study of the reactogenicity and antigenic activity of a chromatographic cultural purified concentrated inactivated dry vaccine against tick-borne encephalitis, Zh. Mikrobiologii, Epidemiologii, Immunobiologii 62:34-39
22. Rothman AL 2003 Immunology and immunopathogenesis of dengue disease. Adv Vir Res 60:397-419
23. Rowland IR 2002 Genetically modified foods, science, consumers and the media. Proc Nutr Soc 61:25-29
24. Seligman SJ, Gould EA 2004 Live flavivirus vaccines: reasons for caution. Lancet 363:2073-2075
25. Stephenson JR 1988 Flavivirus vaccines. Vaccine 6:471-480
26. Stephenson JR 2001 Genetically modified viruses; vaccines by design. Curr Pharmaceut Biotech 2:47-76
27. Stephenson JR 2002 Will the current measles vaccines ever eradicate measles? Expert Rev Vaccines 11:355-362
28. Stephenson JR 2005 Understanding dengue pathogenesis: implications for -vaccine design. Bull WHO 83:308-314
29. Stephenson JR, Bailey N, Lee JM, Shepherd AG, Melling J 1991 Adjuvant effect of HGH with an inactivated flavivirus vaccine. J Inf Dis 164:188-191
30. Stephenson JR, Lee JM, Easterbrook LM, Timofeev AV, Elbert LB 1995 Rapid vaccination protocols for commercial vaccines against tick-borne encephalitis. Vaccine 13:743-746
31. Timofeev AV, Butenko AV, Stephenson JR 2004 Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from TBE virus and dengue 2 virus. Virus Genes 28:81-93
32. Venugopal K, Gould EA 1994 Towards a new generation of flavivirus vaccines. Vaccine 12:996-975
33. Volpina OM, Volkova TD, Koroev DO et al 2005 A synthetic peptide from the NS1 nonstructural protein of tick-borne encephalitis virus induces protective immune response against fatal encephalitis in an experimental animal model. Virus Res 112:95-99